

Dallah posted a disappointing set of result in Q2-19 with net profit of SAR 15.3mn, significantly below AJC's and the market consensus estimates. The result was mainly affected by higher than expected COGS, finance expenses, and OPEX. Higher COGS was largely due to the increase in startup OPEX for Namar Hospital, which started operations in Q2-18. The rise in OPEX was due to higher depreciation expenses and operating cost related to the hike in operating levels at Namar Hospital. The increase in financing cost due to greater operating leverage for Namar Hospital and larger company investments also adversely impacted the results. Revenue was in line with our estimates. **"Neutral"** recommendation on the stock with a TP at SAR 54.20/share.

- Dallah posted net income of SAR 15.3mn in Q2-19 (EPS of SAR 0.13), missing AJC's and the market consensus estimates of SAR 31.5mn and SAR 32.8mn, respectively. The deviation of Q2-19 net income from our estimates is mainly ascribed to a lower than expected gross margin owing to higher startup operating expenses at Namar Hospital. The rise in operating levels at Namar Hospital led to higher OPEX. Financing costs also increased on account of increased operating leverage for the hospital. Pre-operating costs increased at Dr. Mohammed Alfaqih Hospital in which the company holds a stake.
- Dallah's sales in Q2-19 stood at SAR 286.0mn, reflecting an increase of 4.7% Y/Y, in line with our estimate of SAR 286.3mn.
- Gross profit stood at SAR 92.5mn, indicating a rise of 0.1% Y/Y. The GP Margin further declined to 32.3% in Q2-19 from 33.8% in Q2-18 against our estimate of 36.0%. Operations at Namar Hospital, which commenced in Q2-18, continue to have an impact on the margin.
- Operating profit stood at SAR 18.1mn, depicting a decline of 8.1% Y/Y. The company witnessed an increase of 2.3% Y/Y in OPEX (SG&A) to record SAR 74.4mn compared to our estimates of SAR 70.2mn and SAR 72.7mn posted in Q2-18.

**AJC view:** We believe the operations at Namar Hospital, which commenced in Q2-18, continue to have an adverse impact on the company's profit. We believe it would take a couple of years for margins to increase as full capacity expansion would take effect by FY-21. Increased capacity utilization at Namar Hospital and the new hospital opening at Al-Nakheel would constitute key revenue growth drivers. The company's retail-based model places it in a favorable position over its peer set with respect to receivables. However, Dallah needs to make prudent capital allocation decisions while executing its expansion plans due to a high net debt/EBITDA ratio of 3.5x. We lower EPS for FY19 to SAR 1.51 compared to our previous estimate of SAR 1.91. **"Neutral"** recommendation on Dallah with a TP at **SAR 54.20/share**.

#### Results Summary

SARmn (unless specified)	Q2-18	Q1-19	Q2-19	Change Y/Y	Change Q/Q	Deviation from AJC Estimates
Revenue	273.1	321.1	286.0	4.7%	-10.9%	-0.1%
Gross Profit	92.4	120.3	92.5	0.1%	-23.1%	-10.3%
<i>Gross Margin</i>	<i>33.83%</i>	<i>37.46%</i>	<i>32.34%</i>	-	-	-
EBIT	19.7	41.2	18.1	-8.1%	-56.1%	-45.0%
Net Profit	18.7	35.2	15.3	-18.2%	-56.5%	-51.4%
EPS	0.16	0.29	0.13	-	-	-

Source: Company Reports, Aljazira Capital \*NM: Not meaningful

## Neutral

Target Price (SAR) **54.20**

Upside / (Downside)\* **-2.2%**

Source: Tadawul \*prices as of 28<sup>th</sup> of July 2019

#### Key Financials

SARmn (unless specified)	FY17	FY18	FY19E
Revenues	1,212.1	1,180.9	1,226.9
Growth %	4.2%	-2.6%	3.9%
Net Income	295.0	141.8	113.2
Growth %	31.3%	-51.9%	-20.2%
EPS	5.00	1.89	1.51

Source: Company reports, Aljazira Capital

#### Key Ratios

SARmn (unless specified)	FY17	FY18	FY19E
Gross Margin	46.0%	36.9%	35.0%
Net Margin	24.3%	12.0%	9.2%
P/E	20.2x	23.4x	36.7x
P/B	3.5x	2.0x	3.7x
EV/EBITDA (x)	17.5x	18.2x	24.1x

Source: Company reports, Aljazira Capital

#### Key Market Data

Market Cap (bn)	4.1
YTD %	+17.8%
52 Week High/ Low	59.77/39.40
Shares Outstanding (mn)	75

Source: Company reports, Aljazira Capital

#### Price Performance



Source: Tadawul, Aljazira Capital

Head of Research

Talha Nazar

+966 11 2256250

t.nazar@aljaziracapital.com.sa



RESEARCH DIVISION

Head of Research  
**Talha Nazar**  
+966 11 2256250  
t.nazar@aljaziracapital.com.sa

Senior Analyst  
**Jassim Al-Jubran**  
+966 11 2256248  
j.aljabran@aljaziracapital.com.sa

Analyst  
**Abdulrahman Al-Mashal**  
+966 11 2256374  
A.Almashal@Aljaziracapital.com.sa

BROKERAGE AND INVESTMENT CENTERS DIVISION

General Manager – Brokerage Services & sales  
**Alaa Al-Yousef**  
+966 11 2256060  
a.yousef@aljaziracapital.com.sa

AGM-Head of international and institutional brokerage  
**Luay Jawad Al-Motawa**  
+966 11 2256277  
lalmutawa@aljaziracapital.com.sa

AGM-Head of Qassim & Eastern Province  
**Abdullah Al-Rahit**  
+966 16 3617547  
aalrahit@aljaziracapital.com.sa

AGM-Head of Sales And Investment Centers  
Central Region, & acting head Western and Southern Region Investment Centers  
**Sultan Ibrahim AL-Mutawa**  
+966 11 2256364  
s.almutawa@aljaziracapital.com.sa

RESEARCH DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING TERMINOLOGY

- Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
- Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
- Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
- Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

## Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Corporate Finance | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia. Tel: 011 2256000 - Fax: 011 2256068